Yüklüyor......
Targeting TBK1 Inhibits Migration and Resistance to MEK Inhibitors in Mutant NRAS Melanoma
Melanoma is a devastating form of skin cancer with limited therapeutic options. Fifteen to twenty percent of melanoma patients have an activating mutation in the GTPase, NRAS. The major downstream effectors of RAS are RAFs (ARAF, BRAF, CRAF), phosphatidylinositol 3-kinase (PI3K), and the Ral guanine...
Kaydedildi:
| Yayımlandı: | Mol Cancer Res |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2014
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4482471/ https://ncbi.nlm.nih.gov/pubmed/24962318 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1541-7786.MCR-14-0204 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|